Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Series B round brings in $74mm for EpimAb

Executive Summary

EpimAb Biotherapeutics Inc. (bispecific antibodies for cancer) raised $74mm through its Series B round co-led by new board members SDIC Fund and Sherpa Healthcare Partners. Also participating were SCVC, private investment entities, and Series A investors. The company uses its FIT-Ig (Fabs-In-Tandem Immunoglobulin) technology to generate immuno-oncology bispecifics with antibody-like properties; lead candidate EMB01 is in preclinical studies.
Deal Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies